Novartis AG (NVS)

CH — Healthcare Sector
Peers: AZN  GSK  RHHBY  BMY  SNY  MRK  BAYRY  GILD  JNJ  ABBV  LLY  PFE 

Automate Your Wheel Strategy on NVS

With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NVS
  • Rev/Share 26.8608
  • Book/Share 19.5386
  • PB 5.9375
  • Debt/Equity 0.815
  • CurrentRatio 0.7941
  • ROIC 0.1778

 

  • MktCap 228636423956.0
  • FreeCF/Share 7.5442
  • PFCF 15.3995
  • PE 17.7164
  • Debt/Assets 0.3129
  • DivYield 0.0345
  • ROE 0.3071

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NVS UBS Buy Neutral -- -- Feb. 13, 2025
Initiation NVS Morgan Stanley -- Underweight -- -- Feb. 12, 2025
Upgrade NVS Deutsche Bank Hold Buy -- -- Feb. 4, 2025
Downgrade NVS HSBC Securities Hold Reduce -- -- Dec. 4, 2024
Downgrade NVS BofA Securities Buy Neutral $135 $130 Sept. 11, 2024
Downgrade NVS Goldman Buy Neutral -- -- Sept. 5, 2024
Downgrade NVS Jefferies Buy Hold -- -- Sept. 3, 2024

News

Novartis' Pluvicto shown to slow prostate cancer in earlier setting
NVS
Published: June 02, 2025 by: Reuters
Sentiment: Positive

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered.

Read More
image for news Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
NVS
Published: June 02, 2025 by: WSJ
Sentiment: Positive

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Read More
image for news Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
NVS
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, …

Read More
image for news Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
DORM, ENGIY, MTZ, NVS, STRL
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive

NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.

Read More
image for news Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
Are You Looking for a High-Growth Dividend Stock?
NVS
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?

Read More
image for news Are You Looking for a High-Growth Dividend Stock?
Here's Why Novartis (NVS) is a Strong Value Stock
NVS
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Here's Why Novartis (NVS) is a Strong Value Stock
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
NVS
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Should Value Investors Buy Novartis (NVS) Stock?
NVS
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Should Value Investors Buy Novartis (NVS) Stock?
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
ABBV, AMGN, BIIB, BMY, GILD, JNJ, LLY, MRK, NVO, NVS, PFE, REGN, RHHBY, UNH, XBI
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.

Read More
image for news Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Novartis to keep making malaria drugs if orders dry up amid aid cuts
NVS
Published: May 12, 2025 by: Reuters
Sentiment: Positive

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview.

Read More
image for news Novartis to keep making malaria drugs if orders dry up amid aid cuts
Here's Why Novartis (NVS) is a Strong Momentum Stock
NVS
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Novartis (NVS) is a Strong Momentum Stock
Novartis (NVS) is a Great Momentum Stock: Should You Buy?
NVS
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read More
image for news Novartis (NVS) is a Great Momentum Stock: Should You Buy?
Why Novartis (NVS) is a Great Dividend Stock Right Now
NVS
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?

Read More
image for news Why Novartis (NVS) is a Great Dividend Stock Right Now
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
NVS, RGLS
Published: April 30, 2025 by: Benzinga
Sentiment: Positive

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

Read More
image for news Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Why Novartis (NVS) is a Top Value Stock for the Long-Term
NVS
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Novartis (NVS) is a Top Value Stock for the Long-Term
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
EXAS, NVS
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read More
image for news These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
NVS
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive

Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investment, bolstering our positive outlook amid pharma tariff uncertainties. It also raised its FY 2025 outlook. Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy rating.

Read More
image for news Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
NVS
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing.

Read More
image for news Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
Novartis to Acquire Regulus in $1.7 Billion Deal
NVS
Published: April 30, 2025 by: WSJ
Sentiment: Positive

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

Read More
image for news Novartis to Acquire Regulus in $1.7 Billion Deal
Novartis to buy Regulus Therapeutics for up to $1.7 billion
NVS, RGLS
Published: April 30, 2025 by: Reuters
Sentiment: Positive

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

Read More
image for news Novartis to buy Regulus Therapeutics for up to $1.7 billion
Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
NVS
Published: April 29, 2025 by: CNBC Television
Sentiment: Neutral

Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.

Read More
image for news Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
NVS
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral

Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Florent Cespedes - Bernstein Peter Verdult - BNP Paribas Exane Richard Vosser - JPMorgan James Quigley - Goldman Sachs Thibault Boutherin - Morgan Stanley Matthew Weston - UBS Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Steve Scala - TD Securities Operator Good morning and good afternoon, and welcome …

Read More
image for news Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
NVS
Published: April 29, 2025 by: CNBC Television
Sentiment: Positive

Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.

Read More
image for news Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
Pharma firms maastraz
AZN, GSK, NVO, NVS
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral

Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.

Read More
image for news Pharma firms maastraz
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
NVS
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
NVS
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive

NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance.

Read More
image for news Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
Novartis Lifts Guidance After Profit, Sales Top Views
NVS
Published: April 29, 2025 by: WSJ
Sentiment: Positive

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.

Read More
image for news Novartis Lifts Guidance After Profit, Sales Top Views
Novartis more upbeat on 2025 guidance after strong Q1 momentum
NVS
Published: April 29, 2025 by: Reuters
Sentiment: Positive

Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.

Read More
image for news Novartis more upbeat on 2025 guidance after strong Q1 momentum
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
JNJ, NVS
Published: April 26, 2025 by: The Motley Fool
Sentiment: Negative

President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days.

Read More
image for news These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
NVS
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

About Novartis AG (NVS)

  • IPO Date 1996-11-07
  • Website https://www.novartis.com
  • Industry Drug Manufacturers - General
  • CEO Dr. Vasant Narasimhan M.D.
  • Employees 75883

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.